Impax Laboratories Appoints Mark A. Schlossberg as Senior Vice President and General Counsel

May 2, 2011

HAYWARD, Calif., May 02, 2011 (BUSINESS WIRE) -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today the appointment of Mark A. Schlossberg as Senior Vice President and General Counsel. In this role, Mr. Schlossberg will report to Impax's President and Chief Executive Officer and be responsible for all of Impax's legal affairs.

Mr. Schlossberg brings over 25 years of legal experience to Impax, including more than 11 in the healthcare industry. He joins Impax from Amgen Inc., where he served as Vice President, Associate General Counsel, responsible for the areas of corporate governance and securities law, licensing, mergers and acquisitions, sales and marketing and global operations. Prior to joining Amgen, he held legal and business positions at Medtronic, Inc., and legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. He earned a Bachelor of Sciences in business administration and finance from the University of Southern California and a Juris Doctor degree from Emory University.

Larry Hsu, Ph.D., president and CEO of Impax said, "We are very pleased that Mark joins Impax as our General Counsel. He is an accomplished executive with extensive legal and business leadership experience. Impax has experienced significant growth the past several years and his addition further enhances our management team."

About Impax Laboratories, Inc.

Impax Laboratories, Inc. ("Impax") is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Website at: www.impaxlabs.com.

SOURCE: Impax Laboratories, Inc.

Impax Laboratories, Inc.
Mark Donohue
Sr. Director Investor Relations and Corporate Communications
215-558-4526
www.impaxlabs.com